Eli Lilly has spent the last decade transforming from a reliable but unremarkable dividend payer into one of the most talked-about stocks on Wall Street.
Its obesity and diabetes franchise, built around tirzepatide, the active ingredient in both Zepbound and Mounjaro, has sent the dividend stock soaring and reshaped how investors think about the pharmaceutical sector.
Valued at a market cap of $883 billion, Eli Lilly (LLY) stock has returned more than 1,500% in the past decade, after adjusting for dividend reinvestments. Despite these outsized gains, it is down 13% from all-time highs.
Lilly brought in $65.2 billion in revenue last year, a jaw-dropping 45% growth rate for a company that’s been around since 1876.
But HSBC just dropped a blunt verdict on the stock, and it’s one that income investors should take seriously.
HSBC turns bearish on Eli Lilly stock
HSBC downgraded LLY stock to “reduce” from “hold” and cut its price target to $850 from $1,070. With the stock currently trading near $989, that target implies meaningful downside from today’s level.
The firm’s concern isn’t that Lilly is a bad company. It’s that expectations have run too hot.
Related: Eli Lilly’s pill solves the biggest problem with weight loss
Wall Street broadly assumes the obesity drug market will eventually surpass $150 billion. HSBC’s own estimate puts the total addressable market somewhere between $80 billion and $120 billion by 2032, a wide gap that could leave investors disappointed.
The bank also pointed to pricing pressure as a serious issue. Price cuts in 2026 represent a clear headwind for Lilly, and HSBC suggested that much of the recent sales momentum is being driven more by pricing dynamics than true product differentiation.
LLY stock dividend snapshot
Eli Lilly has paid a dividend for almost 30 years and has raised the payout for 12 consecutive years, according to Fiscal.ai data. Since 2014, Eli Lilly has increased its dividend at an annual rate of 11%.
Analysts forecast the health care heavyweight to increase free cash flow from $9 billion in 2025 to over $47 billion in 2030.
More Dividend Stocks:
- Dividend-paying restaurant stock stumbles as gas prices surge
- Megacap dividend stock may make sweeping layoffs to offset AI costs
- 156-year-old energy giant to pay $17 billion in dividends as oil spikes to $110
Given an annual dividend expense of $6.2 billion, Eli Lilly has enough room to raise dividends at an accelerated pace.
Wall Street estimates the dividend payout to almost double through 2030.
But its yield is modest given how much the stock has appreciated. Here’s what investors should know.
- Annual dividend: Approximately $6.92 per share
- Dividend yield: Roughly 0.70% (based on a share price of about $989)
- 12-year dividend growth rate: Approximately 11% annually
- Consecutive years of dividend payout: 29 years
- Ex-dividend frequency: Quarterly
The low yield won’t attract income-focused investors looking for immediate cash flow. But the low payout ratio and double-digit dividend growth rate signal that Lilly has the capacity to keep raising its dividend well into the future, even as it continues to invest aggressively in its pipeline.
Orforglipron launch may disappoint
One of the biggest wild cards heading into the second half of 2026 is the launch of orforglipron: Lilly’s oral obesity pill, awaiting Food and Drug Administration approval, expected as early as April.
HSBC flagged that compliance and persistence rates for oral drugs may underperform expectations, and that discontinuation rates seen in clinical trials suggest the market is getting ahead of reality.
Porrini/Shutterstock
Eli Lilly CFO Lucas Montarce pushed back on that skepticism during the Cowen conference, saying Lilly feels “really good” about the product profile and highlighted a key convenience advantage.
Unlike Novo Nordisk’s Wegovy pill, which requires patients to take it with limited water and wait 30 minutes before eating, orforglipron has no such food or water restrictions.
Montarce also noted the drug is a daily treatment where ease of use will matter over time.
Still, Novo Nordisk’s oral Wegovy reached 50,000 weekly prescriptions in under three weeks, CNBC reported. Lilly will be entering a market where the competition already has a head start and brand recognition working in its favor.
Related: The Dow’s best dividend stocks: A shortlist for income investors
What LLY stock investors should watch
HSBC’s downgrade isn’t a death sentence for LLY. Wall Street price targets for the stock range from $850 to $2,000, which tells you just how wide the disagreement is right now.
The near-term story hinges on orforglipron’s approval and early launch performance. If the pill gains traction with patients who’ve been waiting for a convenient oral option, the bears could look foolish quickly.
If compliance rates disappoint or pricing pressure bites harder than expected, HSBC’s $850 target starts to look a lot more reasonable.
For long-term dividend investors, the bigger picture is this:
- Lilly has nearly quadrupled in size over the last decade.
- Its pipeline extends well beyond obesity into cardiovascular disease, oncology, Alzheimer’s disease, and immunology.
- And with Medicare coverage for anti-obesity medications set to begin no later than July 1, volume could expand in ways that help offset the pricing headwinds.
HSBC may be right that the stock is priced for perfection. But the company itself is far from a broken story.
Related: Barclays names 2 drug stocks investors should own in 2026
